Geotechnical Study Sample Clauses

Geotechnical Study. Vol. 8.1
Sample 1Sample 2
AutoNDA by SimpleDocs
Geotechnical Study. The purpose of the geotechnical investigation is to characterize the geotechnical conditions impacting any proposed trenchless pipelines. The geotechnical investigation will provide geotechnical recommendations relative to the design and construction of the proposed pipeline crossing by trenchless methods. Six (6) exploratory borings are proposed along new improvements at Trojan Way, Orange Ave, Vale Way, 58th Street, and Estele Street. The borings will be drilled at least 5 ft below the proposed pipeline invert elevation. Therefore, boring depths of between 15 and 50 ft below ground surface (bgs). A truck-mounted, small- diameter, hollow-stem auger drill rig is proposed to advance borings to the target depths, however, an air-rotary or air- percussion drill rig may be substituted if effective refusal is encountered during auger drilling. The purpose of the geotechnical investigation will be to evaluate the geotechnical conditions along these pipeline reaches of the alignment and provide geotechnical recommendations relative to the design and construction of the proposed water pipeline. The proposed scope of services may include the following and may be modified based on additional site evaluation and Project information: ▪ Research and review of geotechnical maps and literature pertaining to the site and vicinity, including the previous geotechnical report for this Project if available and any nearby projects. ▪ Research and Review of historic aerial photographs, as-built maps and topographic maps of the area to evaluate the presence/depth of fill. ▪ Field reconnaissance to observe the existing surficial soil conditions along the alignment and to mark out proposed exploratory boring locations. ▪ Communications with Underground Services Alert (USA) agency representatives to check that the proposed subsurface investigation will not affect known buried utilities. ▪ Prepare support data map for City’s IB-511 review process which include boring and test pit locations, proposed equipment, and access routes. ▪ Prepare photolog of existing conditions and access route in support of IB- 511 document. ▪ Backfill boring locations in accordance with San Diego County Department of Environmental Health requirements. Patch the boring location in accordance with SDG-123. ▪ Geotechnical laboratory testing of the soil samples obtained. Laboratory tests are anticipated to include, at a minimum, grain-size classification, expansion index, Atterberg limits, moisture/density, m...
Sample 1
Geotechnical Study. It is assumed due to the existence of structures and underground systems at the facility, and to the assumption that subsurface problems have not been encountered in the past, that a site- specific geotechnical will not be required; 03/04/19 Stillwater Technologies, Inc. Page 2 of 3 File: 19-036 Canaveral Constr - Brev Schls Rockledge PM Stillwater proposes to provide these services on Lump Sum basis as described above. Out-of-scope items will be addressed in accordance with our Standard Rate Schedule (Attachment ‘A’). Attached also, please find our Standard Services Agreement (Attachment ‘B’). If this proposal is acceptable, please sign the Services Agreement for the Phase I services and return it to us. Should you have any questions or require additional information, please do not hesitate to call me at 407-206- 7222 x 208. Best Regards, STILLWATER TECHNOLOGIES, INC. Xxxxxxx Xxxx Xxxxxxxxx X. Xxxxxx, P.E. Project Manager Principal Engineer Attachments: ‘A’ – Stillwater Rate Schedule ‘B’ – Services Agreement Cc: Stillwater Proposal File 03/04/19 Stillwater Technologies, Inc. Page 3 of 3
Sample 1
Geotechnical Study. 16 Traffic Control 17 Borings 18 Geotechnical Evaluation Report
Sample 1
Geotechnical Study. Summary: Geotechnical Investigation for Xxxxxxx Project prepared by Xxxxx Xxxxxx Xxxxxx, Inc. for Xxxx- Xxxxxxxx, Inc. dated 09/09/99 and 10/19/99 Letter Supplement to Geotechnical Report with Field Resistivity Survey and Chemical Corrosion Tests
Sample 1
Geotechnical Study. The Contractor shall perform and have full responsibility for the comprehensive geotechnical study (the “Geotechnical Study”) which shall indicate the results of Contractor’s full investigation, discovery, and conclusions regarding the subsurface conditions and all other geotechnical issues at the Site. The findings and conclusions of the Geotechnical Study shall be incorporated into the design of the Project.
Sample 1
Geotechnical Study. The Professional shall conduct a subsurface investigation of the proposed tank site to establish subsurface ground conditions. The Professional shall conduct drilling operations to collect samples that shall be used to determine the relative strength of supporting soils in areas where the tank shall be constructed. The Professional shall present data from this study in a geotechnical data report to NBU that will be issued as part of the construction documents.
Sample 1
AutoNDA by SimpleDocs

Related to Geotechnical Study

  • Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Environmental Studies Promptly conduct and complete, at Borrower’s expense, all such investigations, studies, samplings and testings as may be requested by Lender or any governmental authority relative to any substance, or any waste or by-product of any substance defined as toxic or a hazardous substance under applicable federal, state, or local law, rule, regulation, order or directive, at or affecting any property or any facility owned, leased or used by Borrower.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

Time is Money Join Law Insider Premium to draft better contracts faster.